Academy ’25: DOT™ Spectacle Lens 18-Month Data Affirm Powerful Myopia Control

New Data Plus Additional Presentations from SightGlass Vision Bolster Evidence on Real-World Outcomes and Astigmatic Stability for DOT™ Lenses

DALLAS, October, 2025—New 18-month data show that more than half of children wearing DOT™ spectacle lenses experienced no clinically meaningful myopia progression—nearly four times the rate seen in children wearing standard single-vision spectacle lenses.¹ These findings, along with other new research being presented by SightGlass Vision at the American Academy of Optometry 2025 Annual Meeting in Boston, further strengthen the growing body of evidence behind contrast management, which powers the company’s unique Diffusion Optics Technology myopia control solution by softly scattering light before it hits the retina.²

The new update presented by Jennifer Hill on Oct. 9, Control of myopia using contrast modulation spectacle lenses in a Chinese population: 18-month results, shares interim findings from SightGlass Vision’s ongoing study involving patients across five Chinese hospitals. Building on earlier 12-month results, which showed that SightGlass Vision’s Diffusion Optics Technology (DOT 0.2) can slow average myopia progression by up to 75% after 12 months of wear across diverse populations,³ the 18-month data found that 57% of children wearing DOT lenses had no clinically meaningful myopia progression at all, compared to just 15% in the control group.¹ These results also show significant effects on axial length elongation and cycloplegic spherical equivalent refraction progression, with DOT lens wearers exhibiting 0.34 mm and 0.70 D less than the control group, respectively. ¹

Results from Canada further demonstrate the success of DOT lenses in everyday practice. Two-year real-world effectiveness of myopia control contrast modulation spectacle lenses in a Canadian practice, presented by Dr. Kylvin Ho of CU Vision in British Columbia on Oct. 9, reports clinical outcomes primarily from Asian Canadian children, with particular focus on younger children with the highest unmet need due to fast myopic progression. After two years, the proportion of patients with stable refraction (0.50D change or less) was 52% for younger children aged 6-7 and 62% for older children aged 8-10, with DOT lenses slowing myopia progression by at least half on average across the practice.⁴

“We are presenting compelling research at Academy ’25 that reinforces the efficacy of DOT lenses,” said Andrew Sedgwick, CEO of SightGlass Vision. “Momentum continues to grow, with over one million children having worn DOT lenses, and we recently expanded into the U.K. through an early access launch. DOT is becoming a globally trusted solution for protecting children’s vision, and we are grateful for the opportunity to share new insights with our colleagues and to drive more progress in the urgent fight against childhood myopia.”

Dr. Debbie Laughton will also be presenting new insights into the relationship between DOT lenses and astigmatism. 12-month results from a study of North American children and a study of Chinese children showed that DOT lenses slowed myopic progression but provided no evidence to suggest that the lenses caused an increase in astigmatism.⁵ The proportion of children with astigmatism changed from 87% to 92% in the North American study and from 91% to 88% in the Chinese study after 12-months of wear, with no difference between the control group and the DOT lens wearers.⁵ Additional research into subfoveal choroidal thickening with contrast-, defocus-modulating, and standard single vision lenses will also be presented.

Drs. Debbie Jones, Jill Woods, and Ashley Tucker will present a podium education session developed in association with SightGlass Vision on Oct. 9 at 1:30 p.m. in Room 205 ABC, comparing research on different designs of spectacle lenses for myopia management and offering clinical tips. All other research sessions from SightGlass Vision will be in the Exhibit Hall between 4:30 and 6:30 p.m. on Oct. 9.

SightGlass Vision’s patent-protected DOT lenses have made their commercial debut in several markets, including China, the Netherlands, Israel, Canada, Spain, and the U.K., with over one million children having already worn the lenses.^*† Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International.

For more information, visit SightGlassVision.com.

###

About SightGlass Vision 
SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina — a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International to accelerate commercialization opportunities and expand the myopia management category worldwide.

^*This figure is based on sales data and reflects global usage across multiple regions.

^†SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.

 

Media Contact
Carson Daniels, Senior Counselor
McDougall Communications for SightGlass Vision
+1-315-427-6394 or [email protected]